Optimised plasma sample preparation and LC‐MS analysis to support large‐scale proteomic analysis of clinical trial specimens: Application to the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial

Abstract

AbstractPurposeRobust, affordable plasma proteomic biomarker workflows are needed for large‐scale clinical studies. We evaluated aspects of sample preparation to allow liquid chromatography‐mass spectrometry (LC‐MS) analysis of more than 1500 samples from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial of adults with type 2 diabetes.MethodsUsing LC‐MS with data‐independent acquisition we evaluated four variables: plasma protein depletion, EDTA or citrated anti‐coagulant blood collection tubes, plasma lipid depletion strategies and plasma freeze–thaw cycles. Optimised methods were applied in a pilot study of FIELD participants.ResultsLC‐MS of undepleted plasma conducted over a 45 min gradient yielded 172 proteins after excluding immunoglobulin isoforms. Cibachrome‐blue‐based depletion yielded additional proteins but with cost and time expenses, while immunodepleting albumin and IgG provided few additional identifications. Only minor variations were associated with blood collection tube type, delipidation methods and freeze–thaw cycles. From 65 batches involving over 1500 injections, the median intra‐batch quantitative differences in the top 100 proteins of the plasma external standard were less than 2%. Fenofibrate altered seven plasma proteins.Conclusions and clinical relevanceA robust plasma handling and LC‐MS proteomics workflow for abundant plasma proteins has been developed for large‐scale biomarker studies that balance proteomic depth with time and resource costs.